CRISPR Therapeutics AG (CRSP) financial statements (2020 and earlier)

Company profile

Business Address BAARERSTRASSE 14
ZUG, CH-6300
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments630457240316
Cash and cash equivalents630457240316
Receivables0034
Other undisclosed current assets341051
Total current assets:664466248320
Noncurrent Assets
Operating lease, right-of-use asset31
Property, plant and equipment21191921
Intangible assets, net (including goodwill)0000
Intangible assets, net (excluding goodwill)0000
Restricted cash and investments4333
Other noncurrent assets1110
Total noncurrent assets:57232325
TOTAL ASSETS:721489271345
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities27261321
Accounts payable3525
Accrued liabilities22211116
Taxes payable1000
Deferred revenue48
Debt5   
Deferred rent credit 1
Deferred revenue and credits11
Other liabilities 000
Total current liabilities:80281522
Noncurrent Liabilities
Long-term debt and lease obligation37   
Operating lease, liability37
Liabilities, other than long-term debt12696990
Deferred revenue and credits6990
Deferred revenue12
Contract with customer, liability58
Deferred rent credit 11
Other liabilities0000
Total noncurrent liabilities:49696990
Total liabilities:1299784112
Stockholders' equity
Stockholders' equity attributable to parent592392188233
Common stock2211
Treasury stock, value(0)(0)  
Additional paid in capital846682312289
Accumulated other comprehensive income (loss)(0)(0)0(0)
Accumulated deficit(255)(292)(125)(57)
Total stockholders' equity:592392188233
TOTAL LIABILITIES AND EQUITY:721489271345

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
Revenue, net51
Revenue from related parties2133
Gross profit:2133415
Operating expenses(222)(162)(106)(73)
Operating loss:(9)(159)(65)(68)
Nonoperating income (expense)(1)(5)(2)45
Other nonoperating income (expense)5(1)(0)79
Interest and debt expense   11
Loss from continuing operations before equity method investments, income taxes:(11)(164)(67)(11)
Loss from equity method investments(4)(4)(2)(37)
Other undisclosed income from continuing operations before income taxes44225
Loss from continuing operations before income taxes:(11)(164)(67)(23)
Income tax expense(1)(1)(2)(0)
Net loss:(11)(165)(68)(23)
Net income attributable to noncontrolling interest   0
Net loss available to common stockholders, diluted:(11)(165)(68)(23)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
Net loss:(11)(165)(68)(23)
Other comprehensive income (loss)0(0)0 
Other undisclosed comprehensive loss(0)   
Comprehensive loss:(11)(165)(68)(23)
Comprehensive income, net of tax, attributable to noncontrolling interest   0
Other undisclosed comprehensive loss, net of tax, attributable to parent(0)  (0)
Comprehensive loss, net of tax, attributable to parent:(11)(165)(68)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: